SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008; 135: 14931499.
  • 2
    Casellas F, Rodrigo L, Nino P, et al. Sustained improvement of health-related quality of life in Crohn's disease patients treated with infliximab and azathioprine for 4 years. Inflamm Bowel Dis. 2007; 13: 13951400.
  • 3
    Feagan BG, Reinisch W, Rutgeerts P, et al. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol. 2007; 102: 794802.
    Direct Link:
  • 4
    Lemann M, Mary JY, Colombel JF, et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology. 2005; 128: 18121818.
  • 5
    Viget N, Vernier-Massouille G, Salmon-Ceron D, et al. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut. 2008; 57: 549558.
  • 6
    Toruner M, Loftus EVJr, Hamrsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008; 134: 929936.
  • 7
    Esteve M, Saro C, Gonzalez-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut. 2004; 53: 13631365.
  • 8
    Deutsch DE, Olson AD, Kraker S, et al. Overwhelming varicella pneumonia in a patient with Crohn's disease treated with 6-mercaptopurine. J Pediatr Gastroenterol Nutr. 1995; 20: 351353.
  • 9
    Leung VS, Nguyen MT, Bush TM. Disseminated primary varicella after initiation of infliximab for Crohn's disease. Am J Gastroenterol. 2004; 99: 25032504.
    Direct Link:
  • 10
    Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006; 101: 18341840.
    Direct Link:
  • 11
    Sands BE, Cuffari C, Katz J, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004; 10: 677692.
  • 12
    Stojanovich L. Influenza vaccination of patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Clin Dev Immunol. 2006; 13: 373375.
  • 13
    Nichol KL, Nordin JD, Nelson DB, et al. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med. 2007; 357: 13731381.
  • 14
    Vila-Corcoles A, Ochoa-Gondar O, Hospital I, et al. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis. 2006; 43: 860868.
  • 15
    Confavreux C, Suissa S, Saddier P, et al. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med. 2001; 344: 319326.
  • 16
    Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003; 289: 179186.
  • 17
    Fiore AE, Shay DK, Broder K, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep. 2008; 57: 160.
  • 18
    Mamula P, Markowitz JE, Piccoli DA, et al. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007; 5: 851856.
  • 19
    Lu Y, Jacobson DL, Ashworth LA, et al. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol. 2009; 104: 444453.
  • 20
    Chalmers A, Scheifele D, Patterson C, et al. Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. J Rheumatol. 1994; 21: 12031206.
  • 21
    Fomin I, Caspi D, Levy V, et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis. 2006; 65: 191194.
  • 22
    Del Porto F, Lagana B, Biselli R, et al. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity. Vaccine. 2006; 24: 32173223.
  • 23
    Abu-Shakra M, Press J, Varsano N, et al. Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol. 2002; 29: 25552557.
  • 24
    Holvast A, Huckriede A, Wilschut J, et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis. 2006; 65: 913918.
  • 25
    Kaine JL, Kivitz AJ, Birbara C, et al. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol. 2007; 34: 272279.
  • 26
    Gelinck LB, van der Bijl AE, Beyer WE, et al. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis. 2008; 67: 713716.
  • 27
    Kapetanovic MC, Saxne T, Sjoholm A, et al. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford). 2006; 45: 106111.
  • 28
    Fields SW, Baiocco PJ, Korelitz BI. Influenza vaccinations: should they really be encouraged for IBD patients being treated with immunosuppressives? Inflamm Bowel Dis. 2008 (in press).
  • 29
    Kwon OS, Park YS, Choi JH, et al. [A case of ulcerative colitis relapsed by influenza vaccination.] Korean J Gastroenterol. 2007; 49: 327330.
  • 30
    Sands BE. Response to letter by Field et al, “Influenza vaccinations: should they really be encouraged for IBD patients being treated with immunosuppressives?” Inflamm Bowel Dis. 2008 (in press).
  • 31
    Kroger AT, Atkinson WL, Marcuse EK, et al. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006; 55: 148.
  • 32
    Dotan I, Vigodman S, Malter L, et al. Azathioprine/6-mercaptopurine therapy has no significant effect on cellular or humoral immune responses in patients with inflammatory bowel disease. Gastroenterology. 2007; 132: A51.
  • 33
    Melmed GY, Frenck R, Barolet-Garcia C, et al. TNF blockers and immunomodulators impair antibody responses to pneumococcal polysaccharide vaccine (PPV) in patients with inflammatory bowel disease (IBD). Gastroenterology. 2008; 134( 4 suppl 1 ): A68.
  • 34
    Elkayam O, Caspi D, Reitblatt T, et al. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum. 2004; 33: 283288.
  • 35
    Mease PJ, Ritchlin CT, Martin RW, et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol. 2004; 31: 13561361.
  • 36
    Millonig G, Kern M, Ludwiczek O, et al. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol. 2006; 12: 974976.
  • 37
    Infliximab Package Insert (www.accessdata.fda.gov). 2007.
  • 38
    Adalimumab Package Insert (www.accessdata.fda.gov). 2008.
  • 39
    Certolizumab package insert (www.accessdata.fda.gov). 2008.
  • 40
    Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006; 55: 133; quiz CE1-4.
  • 41
    Elkayam O, Yaron M, Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. Ann Rheum Dis. 2002; 61: 623625.
  • 42
    Update on adult immunization. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep. 1991; 40: 194.
  • 43
    Nielsen HJ, Mortensen T, Holten-Andersen M, et al. Increased levels of specific leukocyte- and platelet-derived substances during normal anti-tetanus antibody synthesis in patients with inactive Crohn disease. Scand J Gastroenterol. 2001; 36: 265269.
  • 44
    Brogan MD, Shanahan F, Oliver M, et al. Defective memory B cell formation in patients with inflammatory bowel disease following tetanus toxoid booster immunization. J Clin Lab Immunol. 1987; 24: 6974.
  • 45
    Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56: 124.
  • 46
    Bhatia J, Bratcher J, Korelitz B, et al. Abnormalities of uterine cervix in women with inflammatory bowel disease. World J Gastroenterol. 2006; 12: 61676171.
  • 47
    Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol. 2008; 103: 631636.
    Direct Link:
  • 48
    Kane S. Abnormal Pap smears in inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14: 11581160.
  • 49
    Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. MMWR Recomm Rep. 1996; 45: 136.
  • 50
    Gershon AA, Steinberg SP. Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine. N Engl J Med. 1989; 320: 892897.
  • 51
    Marin M, Guris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56: 140.
  • 52
    Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006; 4: 14831490.
  • 53
    Korelitz BI, Fuller SR, Warman JI, et al. Shingles during the course of treatment with 6-mercaptopurine for inflammatory bowel disease. Am J Gastroenterol. 1999; 94: 424426.
    Direct Link:
  • 54
    Cetron MS, Marfin AA, Julian KG, et al. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep. 2002; 51: 111; quiz CE1-4.
  • 55
    Izurieta HS, Haber P, Wise RP, et al. Adverse events reported following live, cold-adapted, intranasal influenza vaccine. JAMA. 2005; 294: 27202725.
  • 56
    Kamboj M, Sepkowitz KA. Risk of transmission associated with live attenuated vaccines given to healthy persons caring for or residing with an immunocompromised patient. Infect Control Hosp Epidemiol. 2007; 28: 702707.
  • 57
    Prevention of varicella. Update recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1999; 48: 15.
  • 58
    Cortese MM, Parashar UD. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2009; 58: 125.